https://www.businesswire.com/news/home/20190501005399/en/

CAMBRIDGE, England--(BUSINESS WIRE)--May 1, 2019--Mission Therapeutics (“Mission”), a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), today announced the appointment of Dr. James Summers as an independent member to its Board of Directors, with immediate effect.

Dr. Summers brings over 30 years of drug discovery and pharmaceutical research management experience to Mission’s Board. His most recent position was as Vice President of Neuroscience Research at AbbVie, where he led drug discovery efforts in the treatment of Alzheimer’s and Parkinson’s diseases, pain, and psychiatric disorders.